National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Osimertinib (Tagrisso®) as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.

NCPE Assessment Process Complete
Rapid review commissioned 19/07/2018
Rapid review completed 07/08/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of osimertinib for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations compared with the current standard of care.